Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jul;185(1):177-184.
doi: 10.1111/bjd.19863. Epub 2021 May 4.

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

L M Prens  1 , K Bouwman  1 , P Aarts  2 , S Arends  3 , K R van Straalen  2 , K Dudink  2 , B Horváth  1 , E P Prens  2
Affiliations
Multicenter Study

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

L M Prens et al. Br J Dermatol. 2021 Jul.

Abstract

Background: Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking.

Objectives: To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival.

Methods: A retrospective multicentre study was performed in two academic dermatology centres in the Netherlands. Adult patients with HS using biologics between 2008 and 2020 were included. Drug survival was analysed with Kaplan-Meier survival curves and predictors of survival with univariate Cox regression analysis.

Results: The overall drug survival of adalimumab (n = 104) at 12 and 24 months was 56·3% and 30·5%, respectively, which was predominantly determined by infectiveness. Older age (P = 0·02) and longer disease duration (P < 0·01) were associated with longer survival time. For infliximab (n = 44), overall drug survival was 58·3% and 48·6% at 12 and 24 months, respectively, and was predominantly determined by infectiveness and side-effects. Surgery during treatment was associated with a longer survival time (P = 0·01).

Conclusions: Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan–Meier curves showing (a) the overall cumulative survival per biological agent, and survival related to (b) drug ineffectiveness and (c) to side‐effects. Ada, adalimumab; IFX, infliximab.
See this image and copyright information in PMC

Comment in

References

    1. Alavi A, Anooshirvani N, Kim WBet al. Quality‐of‐life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol 2014; 16:61–5. - PubMed
    1. Janse IC, Deckers IE, van der Maten ADet al. Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross‐sectional study. Br J Dermatol 2017; 176:1042–7. - PubMed
    1. Matusiak Ł, Bieniek A, Szepietowski JC. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010; 90:264–8. - PubMed
    1. Kimball AB, Okun MM, Williams DAet al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 2016; 375:422–34. - PubMed
    1. Zouboulis CC, Okun MM, Prens EPet al. Long‐term adalimumab efficacy in patients with moderate‐to‐severe hidradenitis suppurativa/acne inversa: 3‐year results of a phase 3 open‐label extension study. J Am Acad Dermatol 2019; 80:60–9. - PubMed

Publication types